Glenmark Pharmaceutical Inc recalls ranitidine tablets in US
The tablets are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the United States Food and Drug Administration (USFDA), as per the company's announcement posted on the website of the US health regulator.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Pharmaceuticals | Ranitidine | USA Health | Websites